Unaudited Financial Results for the quarter ended 30.06.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts more than Nifty Microcap 250 and 1.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Samsrita Labs reported a loss of Rs. 27.66 lakhs in Q1 FY26 (ended June 30, 2025), compared to a loss of Rs. 8.72 lakhs in the same quarter last year — the loss widened more than three times year-on-year. Revenue from operations was nil/negligible, with total income also near zero, while total expenses of Rs. 27.66 lakhs (employee costs Rs. 15.53 lakhs + other expenses Rs. 12.10 lakhs) drove the loss. Basic and diluted EPS stood at Rs. (0.19) versus Rs. (0.18) in Q1 FY25. Alongside the results, the board approved a preferential cash allotment of 34.91 lakh equity shares at Rs. 10 each (Rs. 3.49 crore) to non-promoters and a share-swap allotment of 45.50 lakh shares to shareholders of Qrops Advisory Services, making Qrops a 28.62% associate company. The 29th AGM is scheduled for 25th August 2025, and statutory auditor MGR & Co issued a clean (unqualified) limited review report.
The widening quarterly loss with virtually no operating revenue is a red flag for existing shareholders. However, the capital raise (~Rs. 3.49 crore) and the Qrops Advisory share-swap deal suggest the company is trying to pivot to a new business, which also brings significant equity dilution to current holders.